These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 32811187)

  • 1. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
    Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
    Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange.
    Tsai FJ; Nelson LT; Kline GM; Jäger M; Berk JL; Sekijima Y; Powers ET; Kelly JW
    Amyloid; 2023 Jun; 30(2):220-224. PubMed ID: 36444793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
    Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S
    FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
    Cho Y; Baranczak A; Helmke S; Teruya S; Horn EM; Maurer MS; Kelly JW
    Amyloid; 2015; 22(3):175-80. PubMed ID: 26193961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
    Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
    Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tafamidis concentration required for transthyretin stabilisation in cerebrospinal fluid.
    Tsai FJ; Jaeger M; Coelho T; Powers ET; Kelly JW
    Amyloid; 2023 Sep; 30(3):279-289. PubMed ID: 36691999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.
    Cotrina EY; Oliveira Â; Leite JP; Llop J; Gales L; Quintana J; Cardoso I; Arsequell G
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy.
    Tess DA; Maurer TS; Li Z; Bulawa C; Fleming J; Moody AT
    Amyloid; 2023 Jun; 30(2):208-219. PubMed ID: 36399070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
    Capovilla TM; Lalario A; Rossi M; Porcari A; Aimo A; Limongelli G; Emdin M; Merlo M; Sinagra G
    Heart Fail Clin; 2024 Jul; 20(3):333-341. PubMed ID: 38844304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of transthyretin kinetic stability in human plasma using subunit exchange.
    Rappley I; Monteiro C; Novais M; Baranczak A; Solis G; Wiseman RL; Helmke S; Maurer MS; Coelho T; Powers ET; Kelly JW
    Biochemistry; 2014 Apr; 53(12):1993-2006. PubMed ID: 24661308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional Molecular Dynamics and Metadynamics Simulation Studies of the Binding and Unbinding Mechanism of TTR Stabilizers AG10 and Tafamidis.
    Zhou S; Ge S; Zhang W; Zhang Q; Yuan S; Lo GV; Dou Y
    ACS Chem Neurosci; 2020 Oct; 11(19):3025-3035. PubMed ID: 32915538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
    J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response.
    Monteiro C; Mesgarzadeh JS; Anselmo J; Fernandes J; Novais M; Rodrigues C; Powers DL; Powers ET; Coelho T; Kelly JW
    Amyloid; 2023 Mar; 30(1):81-95. PubMed ID: 36178172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
    Connelly S; Mortenson DE; Choi S; Wilson IA; Powers ET; Kelly JW; Johnson SM
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3441-3449. PubMed ID: 28625364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
    Patil MB; Ghode P; Joshi P
    Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
    Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
    J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy.
    Iino T; Nagao M; Tanaka H; Yoshikawa S; Asakura J; Nishimori M; Shinohara M; Harada A; Watanabe S; Ishida T; Hirata KI; Toh R
    Sci Rep; 2024 Sep; 14(1):20508. PubMed ID: 39227655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.